Adverse effects ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ not any improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ not any improvement compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ cardiovascular ‐ hypotension compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ seizure · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ central nervous system ‐ seizures compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL may leads to lower repeated need for tranquillisation needing additional injection… compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Tranquillisation or asleep ‐ not asleep up to 2 hours · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in tranquillisation or asleep ‐ not asleep up to 2 hours compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ need for benzodiazepine during 24 hours · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome ‐ need for benzodiazepine compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
Adverse effects: specific ‐ dystonia · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: specific ‐ dystonia compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not asleep by 12 hours · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep ‐ not asleep by 12 hours compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Global outcome: specific Not sedated at 60 minutes * · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: specific Not sedated at 60 minutes * compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ Aggression ‐ no overall improvement · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ aggression ‐ no overall improvement compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Global outcome: no change at 48 hours CGI · patients to psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome: no change at 48 hours CGI compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients to psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found